Topics

Glioblastoma | Treatment | Radiotherapy | Margins

Home > Publications > Topics > Glioblastoma > Treatment > Radiotherapy > Margins

Di Perri D, Hofstede D, Hartgerink D, Terhaag K, Houben R, Postma AA, Hoeben A, Anten M, Ackermans L, Compter I, Eekers DBP.
Impact of clinical target volume margin reduction in glioblastoma patients treated with concurrent chemoradiation.
Neurooncol Pract. 2023 Oct 27;11(3):249-254. doi: 10.1093/nop/npad071. PMID: 38737612. Observational study. ˍ

Yilmaz MT, Kahvecioglu A, Yedekci FY, Yigit E, Ciftci GC, Kertmen N, Zorlu F, Yazici G.
Comparison of different target volume delineation strategies based on recurrence patterns in adjuvant radiotherapy for glioblastoma.
Neurooncol Pract. 2024 Jan 31;11(3):275-283. doi: 10.1093/nop/npae009. PMID: 38737611. Observational study. ˍ

Holzgreve A, Nitschmann A, Maier SH, Büttner M, Schönecker S, Marschner SN, Fleischmann DF, Corradini S, Belka C, la Fougère C, Bodensohn R, Albert NL, Niyazi M.
FET PET-based target volume delineation for the radiotherapy of glioblastoma: A pictorial guide to help overcome methodological pitfalls.
Radiother Oncol. 2024 Jun 14:110386. doi: 10.1016/j.radonc.2024.110386. PMID: 38880414. Guidelines. ˍ

Ferini G, Scalia G, Harikar M, Zagardo V, Castorina L, Comis A, Boncoraglio A, Chaurasia B, Palmisciano P, Umana GE.
Comparative Analysis of Recurrent Glioblastoma Target Contours via ¹¹C-Methionine, ⁶⁸Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography, and Magnetic Resonance Imaging: Implications for Precision Radiotherapy Planning.
Adv Radiat Oncol. 2024 Jun 4;9(9):101548. doi: 10.1016/j.adro.2024.101548. PMID: 39188994. Case report. ˍ

Tang PLY, Romero AM, Nout RA, van Rij C, Slagter C, Swaak-Kragten AT, Smits M, Warnert EAH.
Amide proton transfer-weighted CEST MRI for radiotherapy target delineation of glioblastoma: a prospective pilot study.
Eur Radiol Exp. 2024 Oct 30;8(1):123. doi: 10.1186/s41747-024-00523-4. PMID: 39477835. Interventional study. ˍ

Karp JM, Kruser TJ.
Contouring with FLAIR: Targeting Peritumoral Edema (and Beyond) in Glioblastoma.
Int J Radiat Oncol Biol Phys. 2025 Mar 13;121(5):1182-1184. doi: 10.1016/j.ijrobp.2024.11.073. PMID: 40089338. Editorial˰ ˍ

Bell JB, Sheriff S, Goryawala MZ, Cullison K, Azzam GA, Meshman J, Abramowitz MC, Ivan ME, de la Fuente MI, Mellon EA.
Defining occult disease in glioblastoma using spectroscopic MRI: implications for clinical target volume delineation.
Radiat Oncol. 2025 May 22;20(1):86. doi: 10.1186/s13014-025-02666-z. PMID: 40405247. Observational study. ˍ

Grosu AL, Weber WA, Graf E, Mix M, Nestle U, Schimek-Jasch T, Wiehle R, Mader I, Würtemberger U, Langen KJ, Niyazi M, Paulsen F, König L, Giordano FA, Spehl I, Bernhardt D, Schymalla MM, Pöttgen C, Semrau S, Brunner T, Hültenschmidt B, Krause BJ, Ciernik IF, Beck J, Baumert BG, Meyer PT, Urbach H, Popp I; GLIAA Study Group.
O-(2-[¹⁸F]fluoroethyl)-L-tyrosine-PET-guided versus contrast-enhanced T1-weighted MRI-guided re-irradiation in patients with recurrent glioblastoma (GLIAA/NOA-10 ARO2013-01): a multicentre, open-label, randomised trial.
Lancet Oncol. 2025 Dec 19:S1470-2045(25)00642-4. doi: 10.1016/S1470-2045(25)00642-4. PMID: 41429128. Interventional study. ˍ